2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2817 Diagnostic yield of germline testing in a real-world cohort of 9,000 patients with a personal and/or family history of hematologic malignancies undergoing multigene panel testing

Brittany Stewart, CGC, PhD, Darren McAffee, PhD2, Erica Vaccari, MS3, Michelle Green, PhD4, Rebecca Previs, MD5, Jonathan Williams, PhD6, Grant Hogg, MS7, Josh Keyes, MS8, Jill Polk, MS9, Wendy McKinnon, CGC10, Gergi Mansour, MD11, Sakshi Jasra, MD12, Kara Landry, MD13, Hetty Carraway, MD, MBA14, Sarah M. Young, MS15
1 Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Illinois, United States
2 Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States
3 Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States
4 Labcorp, Durham, North Carolina, United States
5 Labcorp, Durham, North Carolina, United States
6 Labcorp, San Diego, California, United States
7 Labcorp, San Diego, California, United States
8 Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States
9 Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States, Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States
10 University of Vermont Cancer Center, Burlington, Vermont, United States
11 University of Vermont Cancer Center, Burlington, Vermont, United States
12 University of Vermont Cancer Center, Burlington, Vermont, United States
13 University of Vermont Cancer Center, Burlington, Vermont, United States
14 Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Illinois, United States
15 Labcorp (formerly Invitae Corp.), San Francisco, Illinois, United States

Background: Germline genetic testing for hereditary hematologic malignancies (HHM) can influence therapy, prognosis, surveillance, and donor selection. However, most reports are from relatively small, highly selected, institutional cohorts. We report on the yield of germline pathogenic variants (PVs) in a cohort of patients with personal and/or family history of hematologic malignancies undergoing multigene panel testing (MGPT), including genes associated with hematologic and/or solid tumor risk, at a large clinical laboratory.  

Methods: Retrospective review of adult patients undergoing MGPT from March 2015-July 2026 for clinician-reported (ICD-10 codes and keywords) personal and/or family history of hematologic malignancies/disorders, including myeloid or lymphoid malignancy, bone marrow failure/telomere biology disorder (BMF/TBD), myeloproliferative neoplasm (MPN), multiple myeloma (MM), cytopenia, or other hematologic disorders. Patients were tested for at least 9 “core” HHM genes associated with adult-onset myeloid malignancy (ANKRD26, CEBPA, DDX41, ETV6, GATA2, RTEL1, RUNX1, TERC, TERT). Descriptive statistics were used to report the frequency of PVs in 208 genes, across various panels, associated with high (>50%), moderate (20-50%) or low (<20%) lifetime risk of hematologic malignancies and/or solid tumors. Multivariable logistic regression analyzed odds of identifying a PV stratified by clinico-demographic characteristics.  

Results: A total of 9,005 patients underwent testing: 68% female; 68% White, mean (SD) age at testing: 54 (17). 4,576 (51%) patients had personal history of ≥ 1 hematologic malignancy/disorder: myeloid (N=2046, 23%), lymphoid (2323, 26%), cytopenia (523, 6%), BMF/TBD (468, 5%), MM (446, 5%), MPN (238, 3%), other hematologic disorder (368, 4%). 5,667 (63%) of patients reported family history of hematologic malignancy/disorder, including 4,429 (49%) for which family history was the primary indication for testing. Personal and/or family history of solid tumors was reported in 2,723 (30%) and 2,402 (27%) patients, respectively. 1704 (19%) patients had personal history of solid tumor and hematologic family history. Common ordering patterns: 64% with >100 genes analyzed (mean [SD]: 137 [151]); 84% with acute leukemia/MDS panel; 40% with additional solid tumor panel(s). Sample types included blood (50%), gDNA (22%), buccal swab (15%), and saliva (12%).  

In total, 1,857 (21%) patients were positive for ≥ 1 PV. However, 794 (9%) patients carried only a single PV in a gene associated with autosomal recessive inheritance and 73 (0.8%) had only a possibly mosaic result, resulting in 990 (11%) positive patients with 1048 PVs in 65 genes. 318 (32% of positives, 4% overall) had a PV in a high- or moderate-risk HHM gene, while 835 (84% of positives, 9% overall) had a PV in any high- or moderate-risk gene, including 329/4,429 (7%) patients with only a family history of hematologic malignancy/disorder. The most frequent HHM-specific genes with PV were: DDX41 (160 patients, 1.8% of tested patients), RTEL1 (26, 0.3%), RUNX1 (24, 0.3%), POT1 (24, 0.3%), and TERT (10, 0.1%). Commonly identified genes with solid tumor risk included: CHEK2 (205 patients/8472 tested, 2.4%), BRCA1/2 (103/8522, 1.2%), ATM (97/8998, 1.1%), APC (42/7326, 0.6%; [40/42 with I1307K variant]), and MITF (37/6527, 0.6%).  

Multivariable analysis showed increased odds of a moderate- or high-risk PV in any gene was associated with older age at testing (odds ratio [OR]: 1.1, 95% confidence interval [CI] 1.01-1.11), male sex (OR: 1.4, 1.2-1.7), gDNA sample type (vs. blood) (OR: 1.4, 1.1-1.7), and personal history of myeloid malignancy or multiple hematologic indications (vs. family history of hematologic malignancy/disorder as primary testing indication) (OR: 1.6, 1.2-2.1, OR: 1.5, 1.2-1.9, respectively), while Asian/Pacific Islander race (vs. White) decreased the odds of a PV (OR: 0.52, 0.33-0.83).  

Conclusion: In this clinically diverse cohort of 9,005 patients with personal and/or family history of hematologic malignancies, 1 in 11 had a PV in a gene associated with high or moderate hematologic and/or solid tumor risk. This finding supports consideration of universal germline testing for patients with hematologic malignancies with broad MGPT to identify clinically actionable hematologic and solid tumor predisposition genes. Limitations include limited clinical/histologic data and ascertainment bias due to enriched personal/family history.  

Brittany Stewart, CGC, PhD: No relevant conflicts of interest to declare.